[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Petersen VC, Baxter KJ, Love SB, Shepherd NA: Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut; 2002 Jul;51(1):65-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer.
  • BACKGROUND AND AIMS: There is a need for objective easily determined pathological prognostic parameters in Dukes' B colon carcinoma to allow selection of such patients for further treatment as the role of adjuvant chemotherapy for these patients remains unclear.
  • This study was initiated to assess the influence of pathological factors on prognosis in an unselected prospective series of Dukes' B colonic cancer.
  • METHODS: The Gloucester Colorectal Cancer study, established in 1988, recruited more than 1000 cases.
  • Meticulous pathological assessment of the 268 Dukes' B colonic cancer resections in this series included evaluation of all pathological factors that could influence staging and prognosis.
  • CONCLUSIONS: The cumulative prognostic index allows apportionment of patients with Dukes' B colon cancer into defined prognostic groups, which in turn could allow more objective selection of patients for adjuvant therapy, especially as part of clinical trials.
  • [MeSH-major] Colonic Neoplasms / pathology. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] Cancer. 1995 Aug 15;76(4):564-71 [8625148.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):35-41 [9102259.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):65-70 [9093709.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1096-102 [9097991.001]
  • [Cites] J Clin Pathol. 1997 Apr;50(4):266-7 [9215136.001]
  • [Cites] Support Care Cancer. 1997 Jul;5(4):318-21 [9257429.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1349-54 [9579845.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2135-44 [9610692.001]
  • [Cites] J Clin Pathol. 1998 Jun;51(6):481-2 [9771453.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):849-55 [7490320.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):449-56 [10749603.001]
  • [Cites] Br J Surg. 1980 Jun;67(6):439-42 [7388345.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] Lancet. 1987 Jun 6;1(8545):1303-6 [2884421.001]
  • [Cites] Histopathology. 1987 Mar;11(3):259-72 [2828216.001]
  • [Cites] J Clin Pathol. 1989 Feb;42(2):162-6 [2921357.001]
  • [Cites] Histopathology. 1989 Jun;14(6):613-20 [2759558.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1055-9 [1691810.001]
  • [Cites] J Surg Oncol Suppl. 1991;2:36-41 [1909867.001]
  • [Cites] Stat Med. 1992 Dec;11(16):2093-109 [1293671.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [CommentIn] Gut. 2002 Jul;51(1):6-7 [12077080.001]
  • (PMID = 12077094.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1773289
  •  go-up   go-down


2. Machado NO, Chopra PJ, Al Hamdani A: Pancreatic metastasis from colon carcinoma nine years after a hemicolectomy managed by distal pancreatectomy. A review of the literature regarding the role and outcome of pancreatic resection for colorectal metastasis. JOP; 2010;11(4):377-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis from colon carcinoma nine years after a hemicolectomy managed by distal pancreatectomy. A review of the literature regarding the role and outcome of pancreatic resection for colorectal metastasis.
  • A case of colonic metastasis to the pancreas is reported and the literature is reviewed to assess the role and outcome of pancreatic resection for metastatic tumors from colorectal malignancy.
  • CASE REPORT: A 58-year-old female underwent an emergency left hemicolectomy for an obstructing descending colon growth.
  • The lesion was reported to be adenocarcinoma, Dukes C, with involvement of the serosa and 3 lymph nodes.
  • A postoperative staging CT scan showed no other metastases and she received 6 cycles of FOLFOX chemotherapy (folinic acid, 5-flurouracil and oxaliplatin).
  • She underwent a distal pancreatectomy, and histopathology of the resected specimen confirmed a metastatic tumor from colon cancer.
  • She then received 5 cycles of adjuvant chemotherapy.
  • The time-interval between the diagnosis of colorectal cancer and the detection of pancreatic metastasis varies widely but is approximately 24 months.
  • The median survival time for post-pancreatic resection is 16 months.
  • [MeSH-major] Carcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Female. Humans. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JOP. 2010;11(6):644-5; author reply 650 [21068505.001]
  • (PMID = 20601814.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


3. Garcia V, García JM, Peña C, Silva J, Domínguez G, Hurtado A, Alonso I, Rodriguez R, Provencio M, Bonilla F: Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res; 2006 Apr 1;12(7 Pt 1):2095-100
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
  • PURPOSE: Thymidylate synthase (TS), a critical target in fluorouracil-based chemotherapy, is a prognostic marker in colon carcinomas and a predictor of response to treatment.
  • Tumor RNA has been detected in plasma from cancer patients and is associated with poor prognosis.
  • This is the first study to examine extracellular TS mRNA in plasma from patients with colon carcinoma, and its possible relation with TS promoter enhancer region (TSER) polymorphism.
  • Patients with TS mRNA in plasma had higher levels of TS in tumor tissue than patients without.
  • CONCLUSIONS: Our results suggest that TS mRNA in plasma originated from tumors, it may indicate poor prognosis and might help to classify tumors in Dukes' stages B and C.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. RNA, Messenger / genetics. Thymidylate Synthase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609021.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


Advertisement
4. Ragnhammar P, Hafström L, Nygren P, Glimelius B, SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol; 2001;40(2-3):282-308
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic overview of chemotherapy effects in colorectal cancer.
  • A systematic review of chemotherapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU).
  • This synthesis of the literature on adjuvant and palliative therapy with cytostatics for colorectal cancer is based on 208 scientific articles, including eight meta-analyses and 162 randomised studies.
  • The conclusions reached can be summarized into the following points: The benefit of postoperative adjuvant chemotherapy with fluorouracil and levamisole in patients with colon cancer stage Dukes' C was demonstrated more than ten years ago in two phase III trials.
  • Although this combination has been widely accepted as standard adjuvant treatments for stage Dukes' C colon cancer, there is still debate on whether adjuvant treatment with fluorouracil alone would be equally efficacious.
  • Several phase III trials with postoperative adjuvant chemotherapy with fluorouracil and leucovorin in patients with colon cancer stage Dukes' C have demonstrated a similar statistically significant improvement in disease-free and overall survival in comparison with a control arm.
  • Six months of treatment with fluorouracil and leucovorin is as efficient as twelve months of fluorouracil and levamisole.
  • This treatment is, thus, recommended for routine use.
  • No convincing benefit from adjuvant chemotherapy is proven in colon cancer stage Dukes' B although some randomised trials have shown the same relative survival gain as seen in stage Dukes' C.
  • There is less knowledge on survival benefits from adjuvant chemotherapy for Dukes' stage B and C rectal cancer.
  • In small randomised trials, postoperative radiochemotherapy has, however, improved survival to the same extent as chemotherapy in colon cancer Dukes' stage C.
  • At present, however, the use of portal vein infusion or intraperitoneal therapy outside of a research trial cannot be recommended in the light of the limited effects.
  • In advanced colorectal cancer, chemotherapy may prolong survival, decrease tumour-related symptoms, improve general well-being or maintain it at a high level for a longer time period compared with best supportive care.
  • These effects have been seen using systemic chemotherapy and using regional chemotherapy in patients with metastases limited to the liver.
  • Although the impact on overall survival is modest, i.e. an improvement in median survival of five to six months, treatment is recommended also outside clinical trials.
  • High-dose infusional regimens with modulated fluorouracil may turn out to be superior to conventional bolus regimens, since they result in more tumour regressions, longer times to disease progression and possibly longer survival.
  • Randomised studies of regional therapy, mostly hepatic arterial infusions, of liver metastases in colorectal patients have demonstrated significantly higher response rates than systemic fluorouracil therapy alone without impact on overall survival.
  • Regional therapy in advanced disease cannot be recommended outside of clinical trials.
  • New cytotoxic agents are emerging with antitumour activity similar to fluorouracil-based chemotherapy.
  • Based upon the results of two randomised studies, there is a role for irinotecan as second line therapy for selected patients who have failed first-line therapy with fluorouracil plus leucovorin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Levamisole / administration & dosage. Neoplasm Staging. Palliative Care. Portal Vein. Prognosis. Randomized Controlled Trials as Topic. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441937.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 2880D3468G / Levamisole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 208
  •  go-up   go-down


5. Chung YC, Chang KJ, Yang CC, Lai MT, Hsu CP, Hsueh SF, Peng CC, Fu HH, Chang YF, Yang SD: Association of proline-directed protein kinase FA with tumorigenesis, invasion, and poor prognosis of human colon carcinoma. Cancer; 2002 Nov 1;95(9):1840-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of proline-directed protein kinase FA with tumorigenesis, invasion, and poor prognosis of human colon carcinoma.
  • BACKGROUND: Initial studies revealed that the multisubstrate proline-directed protein kinase F(A) (PDPK F(A)) is overexpressed in various types of human carcinomas relative to normal controls.
  • Suppression of overexpressed PDPK F(A) inhibits the growth of cancer cells, suggesting a role of this PDPK in human malignancy.
  • In this study, we combine immunohistologic, molecular, cellular, animal, and clinicopathologic studies to demonstrate an essential and critical role of PDPK F(A) in progression and poor prognosis of human colon carcinoma.
  • METHODS: The stable antisense clones of human colon carcinoma cells with specific suppression of PDPK F(A) were established for tumorigenesis and invasion studies.
  • In immunohistologic and clinicopathologic studies, the expression and localization of PDPK F(A) were analyzed by immunohistochemical staining of the specimens obtained from human colon carcinoma patients with Dukes Stage B/C.
  • RESULTS: Initial molecular and cellular studies revealed that the antisense clone of colon carcinoma cells (COLO-205) with specific suppression of PDPK F(A) dramatically lost capabilities of adhesion, chemotaxis, and invasion when compared with the parental or control-transfected colon carcinoma cells.
  • This is the first indication of an association of overexpressed PDPK F(A) with colon carcinoma progression.
  • In agreement with this notion, the in vivo study also revealed that the mice injected with the antisense clone with low-level PDPK F(A) only developed very small tumors (< 0.5 cm(3)) even after a 6-week observation.
  • This is in contrast to the parental or control-transfected cells that developed large tumors (> 5 cm(3)) under identical conditions.
  • In contrast, there was no sign of invasion in mice injected with the antisense clone, confirming an essential role of PDPK F(A) in colon carcinoma progression.
  • Clinicopathologic study also revealed that PDPK F(A) is preferentially overexpressed in the invasive area of colon carcinomatous tissues and overexpression of PDPK F(A) is statistically and closely correlated with venous/lymphatic infiltration, lymph node metastasis, and poor prognosis of colon carcinoma patients with Dukes Stage B/C.
  • CONCLUSIONS: The results demonstrate an essential and critical role of overexpressed PDPK F(A) in progression and poor prognosis of colon carcinoma patients.
  • Suppression of overexpressed PDPK F(A) may provide a new powerful adjuvant approach to prevent human colon carcinoma progression and poor prognosis after surgery and chemotherapy.
  • [MeSH-major] Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12404276.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Mross K, Semsek D: [Chemotherapy of colonic carcinoma in the year 2001]. Praxis (Bern 1994); 2001 Mar 22;90(12):497-510
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of colonic carcinoma in the year 2001].
  • [Transliterated title] Die Chemotherapie des Kolonkarzinoms im Jahr 2001.
  • The systemic anticancer drug therapy is indicated in the adjuvant as well as in the palliative setting.
  • There is an indication for an adjuvant therapy in case of Dukes B (stadium II) as well as in Dukes C (stadium III) colon cancer.
  • An indication in the palliative setting remains for the Dukes D (stadium IV) colon cancer patients.
  • Locoregional chemotherapeutical approaches represent no standard procedure and cannot be recommended outside clinical trials because the real value of this therapy is unknown due to a lack of large randomized trials.
  • The mainstay of treatment of colon cancer is 5-Fluoruracil (5-FU), which should be combined with folinic acid in case of bolus (2-4 min. injection) therapy.
  • In the adjuvant situation the Mayo scheme administered over a period of half a year remains the standard of choice because this procedure is validated by large randomized trials and replaces the combination 5-FU + levamisol given over a period of one year in former times.
  • In the palliative situation 5-FU based therapy remains the goldstandard although more options than 5-FU plus folinic acid are now available.
  • Oxaliplatin and irinotecan are approved for the treatment of metastatic colon cancer in first line in combination with 5-FU.
  • Capecitabine and Ralitrexed are drugs, which are approved outside of Germany and can be used as well if indicated.
  • The median survival of patients with metastatic colon cancer is between 12 and 18 month.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Neoplasm Staging. Palliative Care. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11324309.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 61
  •  go-up   go-down


7. Molnar B, Ladanyi A, Tanko L, Sréter L, Tulassay Z: Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res; 2001 Dec;7(12):4080-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients.
  • PURPOSE: Recently several reverse transcription-PCR techniques have been proven to be useful for the detection of circulating micrometastases.
  • In this study, evaluation and modification of a commercial, cytokeratin-based, immunomagnetic cell separation method was performed for the detection of intact cell clusters in colorectal carcinoma patients.
  • EXPERIMENTAL DESIGN: Thirty-two colon cancer patients (6 were in Dukes stage B, 13 in stage C, and 13 in stage D) and 20 healthy donor samples were evaluated.
  • Immunomagnetic cell separation was performed from the buffy coat of peripheral blood samples (20 ml) using the Carcinoma Cell Enrichment Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), avoiding any filtering steps.
  • Follow-up data indicate that chemotherapy cannot destroy all of the circulating tumor cell clusters.
  • CONCLUSIONS: Using the methods presented, we could detect circulating colon cancer cells and cell clusters in colon carcinoma patients.
  • Present data prove that such structures are present in human colorectal cancer, too.
  • [MeSH-major] Colonic Neoplasms / blood. Colorectal Neoplasms / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2002 Jun;8(6):2015; author reply 2016-7 [12060648.001]
  • (PMID = 11751505.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


8. Belhadj N, Gargouri D, Kharrat J, Ben Hriz F, Kochlef A, Kilani A, Romani M, Ghorbel A, Cherif R, Khlifi S, Ben Maamer A, Letaief A: [A gastroenterology unit experience with adjuvant chemotherapy for non-metastatic colon cancer: results from 24 cases]. Tunis Med; 2003 Jun;81(6):395-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A gastroenterology unit experience with adjuvant chemotherapy for non-metastatic colon cancer: results from 24 cases].
  • [Transliterated title] Chimiotherapie adjuvante des cancers coliques non metastatiques. Expérience d'un service de gastro-entérologie. A propos de 24 cas.
  • A prospective study was carried from January 1996 to December 2000 including patients that received adjuvant chemotherapy type FUFOL for colon carcinoma after curative surgery.
  • Chemotherapy was recommended for all stage Dukes B2 end C.
  • Adjuvant chemotherapy was administered to 24 patients (13 men and 11 women, mean age 56.7 +/- 11.5 years) with surgically resected stage B 2 in 7 cases (29%), C in 17 cases (71%).
  • Treatment was completed in 15 patients (62%).
  • With a median follow-up of 31.6 months, 11 patients had no recurrence, one patient had locoregional recurrence and 2 patients developed liver metastasis.
  • Adjuvant FUFOL chemotherapy is actually the recommended adjuvant post-surgical treatment for colon cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma / drug therapy. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Leucovorin / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Hospital Units. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534945.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G, ACOI/GIVIO/GISCAD Investigators: Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst; 2004 May 19;96(10):750-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
  • BACKGROUND: 5-fluorouracil-based adjuvant chemotherapy after surgical resection of colon cancer is standard treatment.
  • In a randomized clinical trial of patients with colon cancer, we compared the benefits of chemotherapy delivered by these routes individually or in combination.
  • METHODS: From April 2, 1992, through April 30, 1998, 1084 eligible patients with Dukes' stage B or C colon carcinoma were randomly assigned: 369 patients to the IP regimen (continuous portal vein infusion of 5-fluorouracil at 500 mg/m2 of body surface daily and heparin at 5000 IU daily for 7 consecutive days, beginning on the day of surgery), 358 patients to the SY regimen (six 28-day courses of systemic leucovorin at 100 mg/m2 daily on days 1 through 5 followed by systemic bolus 5-fluorouracil at 370 mg/m2 daily on days 1 through 5, with treatment initiated 15-35 days after surgery), and 357 patients to the IP+SY regimen (the IP regimen followed by the SY regimen, with the same scheduling).
  • RESULTS: At a median follow-up time of 99 months, 389 events (recurrences, second malignancies, or deaths) had occurred, and 361 patients died.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Portal Vein
  • [MeSH-minor] Administration, Oral. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Italy. Leucovorin / administration & dosage. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Research Design. Risk Factors. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2004 May 19;96(10):727-9 [15150295.001]
  • (PMID = 15150303.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, Iacopetta B: p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology; 2000;58(1):52-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.
  • Two common genetic alterations in colon carcinoma, p53 mutation and microsatellite instability (MSI), were investigated to determine their prognostic importance for cancer-specific survival and response to adjuvant chemotherapy in patients with Dukes' C colon cancer.
  • The cellular response mechanisms to DNA-damaging agents in tumours with mutant p53 or MSI may as a consequence differ, and this might translate into different outcomes following adjuvant chemotherapy.
  • A consecutive series of 388 Dukes' C colon carcinomas with 5-year median follow-up was analysed for p53 mutation and for MSI (in proximal/transverse carcinomas only) using polymerase chain reaction single-strand conformation polymorphism.
  • One hundred and thirty-three patients (34%) received adjuvant chemotherapy (5-fluorouracil/levamisole) with curative intent.
  • The presence of MSI in the proximal/transverse colon carcinoma group was associated with significantly better 5-year survival: 58 versus 32% (p = 0.015, log rank test).
  • This was largely due to better survival observed in the MSI subgroup that received adjuvant chemotherapy (p = 0.017, log rank test).
  • Further work in prospective, randomised clinical trials investigating the effects of adjuvant therapy should consider incorporating MSI status in order to determine whether this is an independent predictive factor for survival and/or response to adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / genetics. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Genes, p53 / genetics. Microsatellite Repeats. Mutation
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Levamisole / administration & dosage. Male. Neoplasm Staging. Polymerase Chain Reaction / methods. Polymorphism, Single-Stranded Conformational. Predictive Value of Tests. Prognosis. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10644941.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B: Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer; 2000 Oct;36(16):2053-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.
  • Previous studies on the prognostic significance of TP53 gene alterations in colorectal cancer (CRC) have led to conflicting results.
  • The present study investigated the prognostic significance of TP53 gene mutation in a very large series of 995 Dukes' B and C CRC patients, the majority of whom did not receive chemotherapy.
  • Mutations were found in 385 (39%) cases and were not associated with tumour stage, histological grade, patient age or sex.
  • Significantly more mutations were found in tumours from the left-sided colon compared with those from the right side (43% versus 34%, P=0.006).
  • TP53 gene mutation had no prognostic value in the overall series or in different site or stage subgroups.
  • None of the different types of TP53 gene mutation showed prognostic value.
  • A trend for association with worse survival was observed in the patient subgroup that received adjuvant chemotherapy (Hazard Ratio (HR) 1.4, 95% confidence interval (CI) 0.89-2.21, P=0.15).
  • These results indicate that mutation of the TP53 gene is not a useful prognostic marker for CRC patients who do not receive adjuvant chemotherapy.
  • Further study is required to determine whether different types of TP53 mutation might be of value in predicting the response of CRC patients to chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Logistic Models. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11044641.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Labianca RF, Beretta GD, Pessi MA: Disease management considerations: disease management considerations. Drugs; 2001;61(12):1751-64
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer is still a majorhealth and social problem.
  • However, many important advances in treatment have been made in the last 4 to 5 years, and more optimism is now justified both among clinicians and patients.
  • In surgically resectable disease, adjuvant chemotherapy has been clearly demonstrated as able to increase overall survival in patients with colon cancer Dukes' stage C, whereas the role of medical treatment in patients with Dukes' stage B colon cancer is still controversial.
  • For rectal cancer, the best adjuvant treatment seems to be represented by radiotherapy (better if administered preoperatively) combined with chemotherapy (usually based on modulated or continuously infused 5-FU).
  • In advanced disease, many new drugs have recently emerged: the most active regimens are those combining an optimal modality of 5-FU administration (i.e. continuous infusion) and one of the most active innovative compounds (irinotecan or oxaliplatin).
  • The role of the oral drugs (e.g. tegafur/uracil, capecitabine) is still under investigation as is the combination of agents excluding 5-FU.
  • It is now recognised that first-line treatment must be offered to all suitable pa- tients, even though asymptomatic, and that a second-line therapy (chiefly with irinotecan) is of value in many patients with cancer that progresses during treatment with 5-FU.
  • From a strategic point of view, the best sequence of drugs/regimens has not yet been defined, while the duration and timing of chemotherapy is still a matter for clinical research.
  • Finally, there is an increasing interest in the role of biological prognostic factors as an aid to a patient-tailored therapy, both in the adjuvant setting and in advanced disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Humans. Liver / physiopathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):459-65 [2957943.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] Radiother Oncol. 1996 Aug;40(2):127-35 [8884966.001]
  • [Cites] Eur J Cancer. 1999 Sep;35(9):1338-42 [10658524.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):35-41 [9102259.001]
  • [Cites] Cancer Causes Control. 2000 Jul;11(6):555-63 [10880038.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):581-5 [8879371.001]
  • [Cites] Lancet. 1995 Feb 11;345(8946):349-53 [7845115.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2296-300 [7964943.001]
  • [Cites] Lancet. 1997 Sep 6;350(9079):681-6 [9291901.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Clin Oncol. 1996 Mar;14 (3):709-15 [8622015.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2528-33 [9667274.001]
  • [Cites] Ann Oncol. 1994 Mar;5(3):233-7 [8186170.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):955-60 [9816066.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):267-74 [7542021.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1421-30 [10526268.001]
  • [Cites] Postgrad Med J. 1996 Aug;72(850):464-9 [8796208.001]
  • [Cites] Ann Surg. 1997 Feb;225(2):193-201 [9065296.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] Ann Oncol. 1996 Nov;7(9):961-5 [9006748.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):893-900 [1735081.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):243-54 [10637236.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):425-32 [2926468.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1177-83 [7909866.001]
  • [Cites] Oncology (Williston Park). 1997 Mar;11(3):295-300, 305; discussion 306 passim [9109124.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1413-20 [11142481.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):353-4 [10972363.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3560-8 [10550155.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):904-11 [1588370.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):373-8 [10972369.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):252-8 [8614003.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):625-30 [2066758.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17 [7932825.001]
  • [Cites] Acta Oncol. 1992;31(6):645-51 [1281650.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):214-9 [9135491.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]
  • (PMID = 11693464.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 70
  •  go-up   go-down


13. Di Costanzo F, Sobrero A, Gasperoni S, Dogliotti L, Frassineti L, Falcone A, Lionetto R, Bruzzi P, Luppi G, Gallo L, Conte P, Comandone A, Turci D, Marzola M, Folco U, Pfanner E, Mestriner M, Boni C, Galli C, Tonato M, Rosso R, Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC): Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol; 2003 Sep;14(9):1365-72
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).
  • BACKGROUND: To determine whether the addition of leucovorin to the combination 5-fluorouracil plus levamisole prolongs disease-free survival and overall survival in patients with radically resected colon cancer (Dukes' B(2-3) and C).
  • CONCLUSIONS: In this trial the schedules used showed no statistically significant differences in terms of disease-free survival or overall survival in the treatment of colorectal cancer.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2003 Sep;14(9):1338-9 [12954571.001]
  • (PMID = 12954574.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 2880D3468G / Levamisole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Adlard JW, Richman SD, Seymour MT, Quirke P: Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol; 2002 Feb;3(2):75-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of the response of colorectal cancer to systemic therapy.
  • Adjuvant chemotherapy with fluorouracil and folinic acid improves overall survival for resected carcinoma of the colon of Dukes' stage C by 10-12%.
  • New treatments with novel molecular targets will soon be entering clinical use.
  • Despite these improvements, many patients undergo chemotherapy for resistant cancer, thus incurring side-effects without benefit.
  • Expression of particular genes can be tested at the protein or RNA level and can be correlated with response or resistance to particular systemic therapies.
  • Thus, predictive-factor testing of tumour biopsy samples may allow us to select chemotherapy or immunotherapy treatments with a high likelihood of benefit for the individual patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Camptothecin / analogs & derivatives. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Biopsy, Needle. Capecitabine. Chemotherapy, Adjuvant. Colectomy / methods. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Predictive Value of Tests. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11902527.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 60
  •  go-up   go-down


15. Seo P: Cases from the medical grand rounds of the Osler Medical Service at Johns Hopkins University. Am J Med; 2002 Jun 15;112(9):730-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two weeks before admission, he developed gradually worsening shortness of breath.
  • One week before admission, he developed a cough that initially was nonproductive but later was associated with hemoptysis.His past medical history was remarkable for a history of colon cancer (Dukes' stage III), for which he underwent a hemicolectomy and treatment with adjuvant chemotherapy in 1993.
  • He also had a history of hypertension, type 2 diabetes, and gout.

  • MedlinePlus Health Information. consumer health - Vasculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12079715.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Catalano V, Loupakis F, Bisonni R, Torresi U, Santini D, Silva RR, Giustini L, Falcone A, D'Emidio S, Rocchi M, Graziano F: Impact of mucinous histology on prognosis for patients with radically resected stage Dukes B2 and C colon cancer: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of mucinous histology on prognosis for patients with radically resected stage Dukes B2 and C colon cancer: Preliminary results.
  • This retrospective analysis was conducted to explore whether mucinous carcinoma (MC) is associated with a worse prognosis than nonmucinous carcinoma (NMC) for patients with Dukes B2 and C radically resected colon cancer.
  • METHODS: We investigated 1,006 unselected patients who underwent curative surgery for sporadic colon cancer and followed up at six Oncology Department between 1998 and 2006.
  • RESULTS: MC accounted for 17.9% (n=180) of all colon carcinomas.
  • MC: M/F 104/76; median age, 68 (range, 28-97); pT1/2/3/4, 1/4/153/22; Dukes B2/C 98/82; invasion 26 (14%); ≥12 examined lymph nodes, 115 (64%); adjuvant chemotherapy, 110 (61%).
  • NMC: M/F 445/381; median age, 68 (range, 29-95); pT1/2/3/4, 9/51/715/51; Dukes B2/C 384/442; invasion 199 (24%); ≥12 examined lymph nodes, 499 (60%); adjuvant chemotherapy, 545 (66%).
  • MC were more frequently located in the proximal colon (54.4% versus 34.6% for NMC; p<0.001).
  • After stratification by stage of disease, MC and NMC had no statistically significant difference in 5-year disease-free survival (Dukes B2: 79.1% and 78.1%, respectively, p=0.86; Dukes C: 53.8% and 56.2%, respectively, p=0.58) and overall survival (Dukes B2: 84.2% and 85.5%, respectively, p=0.80; Dukes C: 68.0% and 67.3% p=0.52).
  • Multivariate analysis using the Cox proportional hazards model showed that the clinically significant prognostic factors were stage at diagnosis (p<0.0001), grading (p<0.0001), and number of lymph node examined (p=0.0002) in the specimen.
  • CONCLUSIONS: In this preliminary analysis, patients with mucinous histology who underwent surgery with curative intent for stage Dukes B2 and C colon cancer had similar prognosis compared to NMC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961242.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kim R, Yamaguchi Y, Toge T: Adjuvant therapy for colorectal carcinoma. Anticancer Res; 2002 Jul-Aug;22(4):2413-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for colorectal carcinoma.
  • Adjuvant therapy for colorectal carcinoma has been developed over the last two decades.
  • We have reviewed the history of adjuvant chemotherapy for colorectal carcinoma in the United States, Europe and Japan with regard to the rationale of the chemotherapy regimen and the survival benefit for the establishment of a standard regimen.
  • Treatment with 5-fluorouracil (5-FU) and leucovorin (LV) for postoperative adjuvant chemotherapy had an overall survival benefit, compared with surgery alone, in randomized controlled trials in the United States and Europe for Dukes' C colon carcinoma.
  • In contrast, the survival benefit of adjuvant chemotherapy for Dukes' B colon carcinoma and for rectal carcinoma has not yet been established.
  • In Japan, randomized controlled trials have examined combination treatment with mitomycin (MMC) and oral fluoropyrimidines for colorectal carcinoma compared with surgery alone.
  • A meta-analysis indicated that combination treatment with MMC and oral fluoropyrimidines had a survival benefit for colorectal carcinoma.
  • The survival benefit of combination treatment with irinotecan (CPT-11) + 5-FU + LV or uracil + tegaful (UFT) + LV (Orzel) for adjuvant chemotherapy are currently being compared with 5-FU + LV.
  • The survival benefit of preoperative radiotherapy was superior to postoperative radiotherapy for advanced rectal carcinoma in association with the prevention of local recurrence.
  • Clinical trial data suggest that the current standard regimen of adjuvant chemotherapy is a combination of 5-FU and LV for Dukes' C colon carcinoma and that radiotherapy for local control of rectal carcinoma has a survival benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174936.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 50
  •  go-up   go-down


18. André T, Tuvignon N, Taieb J, Vaillant JC, Hannoun L, de Gramont A: [Operable colon cancer: initial strategy]. Rev Prat; 2010 Oct 20;60(8):1089-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operable colon cancer: initial strategy].
  • [Transliterated title] Cancer du côlon opérable: quelle stratégie de prise en charge initiale?
  • Individual screening of patients with personal or family history of colon cancer or polyps, or patients with an inflammatory condition of the digestive tract, combined with the generalization of mass screening using Hemoccult, have modified the way colon cancer is diagnosed.
  • The optimization of colon surgery, together with adjuvant chemotherapy, has improved the 5- and 10-year survival.
  • The five-year survival rate is now comprised between 90 percent in patients with stage-I colon cancer, and 65-70 percent in patients with stage-III colon cancer.
  • More than half patients suffer from stage-II (T3-T4 N0) or stage-III (TxN+) cancer, and 30 to 40 percent of these patients experience cancer recurrence without adjuvant therapy within 5 years following surgery.
  • In patients with surgically-resected colon cancer, these recurrences are mostly metastatic (liver, lungs, peritoneum), local recurrences remain uncommon.
  • An adjuvant therapy combining oxaliplatin and fluoropyrimidine is clearly indicated in patients with stage-III colon tumor (20-percent improvement of survival without recurrence), and can be considered in stage-III patients.
  • This treatment is not indicated in patients with stage-I tumor.
  • [MeSH-major] Colonic Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Decision Making. Humans. Neoplasm Recurrence, Local / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21197740.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Cazacu M, Oniu T, Lungoci C, Mihailov A, Cipak A, Klinger R, Weiss T, Zarkovic N: The influence of isorel on the advanced colorectal cancer. Cancer Biother Radiopharm; 2003 Feb;18(1):27-34
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of isorel on the advanced colorectal cancer.
  • There is still no therapy method in the colorectal cancers that is good enough for such a complex disease.
  • Combined surgery, chemotherapy, and radiotherapy improved survival, but the side effects and the poor performance status of the patients seriously affect the use of these methods.
  • We used a therapeutical approach of surgery and chemotherapy combined with biotherapy by Viscum album extract Isorel, aiming to improve the patients' resistance to the disease and to render the treatment's side effects more tolerable.
  • Isorel is aqueous extract well known for its anticancer effects obtained by various in vitro and in vivo experimental models and which was validated by an in vitro bioassay on murine melanoma B16F10 and human cervical carcinoma HeLa cells.
  • Isorel strongly reduced human colon cancer HT 29 cell line growth in vitro in the MTT bioassay.
  • Hence, it was further used in a prospective, randomized, and controlled study which compared the postoperative results for patients with colorectal cancer stages Dukes C (40 patients) and D (24 patients) who, beside surgery, received either only chemotherapy (5-FU), 6 cycles (either the Mayo or the De Gramont protocol) or chemotherapy combined with Isorel biotherapy.
  • These 64 patients were randomly allocated into three groups "only chemotherapy" for 21 cases, chemo + biotherapy for 29 cases and 14 patients underwent only surgery as the control group.
  • The patients operated on and treated with chemo and biotherapy had median survival significantly better and a cumulative proportion survival (Kaplan-Maier) superior to those of the patients receiving only postoperative chemotherapy.
  • Thus, colorectal cancer patients seem to benefit in terms of survival from combined postoperative chemotherapy and Isorel biotherapy, either adjuvant or palliative.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Phytotherapy. Plant Extracts / therapeutic use

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12667306.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isorel M; 0 / Plant Extracts
  •  go-up   go-down


20. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol; 2003 Jan 15;21(2):241-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
  • PURPOSE: To define the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with stage II and III colon carcinoma.
  • PATIENTS AND METHODS: We retrospectively analyzed the prognostic value of TS, Ki-67, and p53 in 706 patients with Dukes' B (291 patients) or Dukes' C (415 patients) colon carcinoma who were treated with either surgery alone (275 patients) or surgery plus fluorouracil (FU)-leucovorin chemotherapy (431 patients) in National Surgical Adjuvant Breast and Bowel Project (NSABP) protocols C01-C04.
  • An interaction with treatment was not identified for any of the markers.
  • CONCLUSION: This retrospective investigation demonstrated that TS, Ki-67, and p53 staining each had significant prognostic value for patients with Dukes' B and C colon carcinoma.
  • However, none of the markers could be used to clearly discern groups of individuals who would be predicted to derive greater or lesser benefit from the use of adjuvant chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / chemistry. Ki-67 Antigen / analysis. Thymidylate Synthase / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Immunoenzyme Techniques. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525515.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA12027; United States / NCI NIH HHS / CA / U10CA37377; United States / NCI NIH HHS / CA / U10CA69651; United States / NCI NIH HHS / CA / U10CA69974
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK, Yang SH, Wang HS, Chen PM: Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol; 2000 Jan;30(1):12-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
  • BACKGROUND: Preoperative carcinoembryonic antigen (CEA) level is considered as a factor predictive of survival in colorectal cancer patients.
  • This study was carried out in an effort to evaluate the prognostic significance of preoperative CEA levels of patients with colorectal cancer in Taiwan.
  • 5-Fluorouracil-based adjuvant chemotherapy was administered if the patients had Dukes' C disease.
  • Reference to the Dukes' classification was according to the classical criteria described in 1932 for carcinoma of the rectum and adapted for use in colonic tumors.
  • By multivariate Cox analysis, lymph node metastases (p = 0.003), penetration of the bowel wall (p = 0.0001) and preoperative CEA levels (p = 0.0001) were found to be independent prognostic factors in colorectal cancer patients.
  • CONCLUSIONS: The data from our study indicate that in addition to lymph node metastases and penetration of the bowel wall, the preoperative CEA levels are also an independent prognostic factor in non-metastatic colorectal cancer patients after curative surgery.
  • This could serve as an appropriate modification to the initial Dukes' scheme in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / blood. Carcinoembryonic Antigen / blood. Colonic Neoplasms / blood. Rectal Neoplasms / blood
  • [MeSH-minor] Age Factors. Analysis of Variance. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Colon / pathology. Female. Fluorouracil / therapeutic use. Forecasting. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. Proportional Hazards Models. Rectum / pathology. Retrospective Studies. Sex Factors. Survival Rate. Taiwan

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Jpn J Clin Oncol. 2000 Nov;30(11):522-3 [11155925.001]
  • (PMID = 10770562.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carcinoembryonic Antigen; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Mitchell MS: Cancer vaccines, a critical review--Part I. Curr Opin Investig Drugs; 2002 Jan;3(1):140-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer vaccines, a critical review--Part I.
  • Cancer vaccines are more properly referred to as 'active specific immunotherapy', and are used to treat cancers rather than to prevent them, at least at present.
  • Vaccines augment already established tumor immunity, are far more specific against the tumor than cytokines, have little or no toxicity, and thus may easily be combined with other types of immunotherapy.
  • Controlled trials of Melacine indicate prolongation of survival in patients with resected stage IIB disease, particularly those with one or more of the following HLA class I alleles: HLA-A2 or -A28 (-A6802), HLA-B12, -44 or -45, and HLA-C3.
  • A combination of interferon-alpha2b and Melacine appears to enhance the anti-tumor response in advanced (stage IV) disease, and is being tested in a large randomized controlled trial in resected stage III disease.
  • An irradiated autologous colon carcinoma vaccine has improved relapse-free survival in resected stage II disease (Dukes B) in a controlled trial.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Humans. Melanoma / drug therapy. Melanoma / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12054065.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 32
  •  go-up   go-down


23. Yip D, Strickland AH, Karapetis CS, Hawkins CA, Harper PG: Immunomodulation therapy in colorectal carcinoma. Cancer Treat Rev; 2000 Jun;26(3):169-90
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunomodulation therapy in colorectal carcinoma.
  • There has been much progress in the understanding of the relationship between the immune system and colorectal cancer.
  • This has led to the use of immunomodulatory therapy in the adjuvant and palliative treatment of the condition.
  • Although attempts at the use of non-specific immunomodulation with agents such as levamisole, cimetidine, alpha interferon and Bacillus Calmette-Guerin (BCG) have not produced significant clinical benefits when tested in randomized trials in both the adjuvant setting and for metastatic disease, promising results are being obtained with more specific therapy.
  • Edrecolomab [corrected], a murine monoclonal antibody targeting the 17-1A antigen on malignant colorectal cells has produced a reduction in relapse and mortality rates when used as adjuvant treatment following surgery for Dukes' C colon cancer.
  • Active specific therapy with autologous tumour vaccine administered with BCG has produced similar benefits in Dukes' B cancer.
  • Immune therapy offers the potential of low toxicity therapy in colorectal cancer and may have a role as an adjunct to conventional chemotherapy.
  • [MeSH-major] Colorectal Neoplasms / therapy. Immunotherapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • [ErratumIn] Cancer Treat Rev 2000 Aug;26(4):313
  • (PMID = 10814560.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic
  • [Number-of-references] 238
  •  go-up   go-down


24. Grothey A, Kellermann L, Schmoll HJ: [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms]. Med Klin (Munich); 2002 May 15;97(5):270-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms].
  • [Transliterated title] Defizite in der Behandlung von Patienten mit kolorektalem Karzinom in Deutschland. Ergebnisse einer multizentrischen Dokumentation von Therapiealgorithmen.
  • BACKGROUND: Adjuvant chemotherapy for patients with UICC III (Dukes C) colorectal cancer (consensus statements NIH 1990, German Cancer Society 1994) and palliative chemotherapy for metastatic disease have long been recognized to provide a survival benefit in colorectal cancer.
  • PATIENTS AND METHODS: Therefore, we asked 74 institutions treating colorectal cancer patients in Germany to document the treatment algorithms of all patients with colorectal cancer seen in the third quarter of 1998.
  • Clinical careers of 1,001 patients (m/f 465/536; median age 62.9 years [28-93]; colon 596, rectum 405; UICC I 117, II 206, III 407, IV 218) were documented.
  • RESULTS: Only 63.4% of patients with UICC III colorectal cancer received adjuvant therapy with a significant difference between hospitals with (67.1%) and without (42.6%) oncological departments (p < 0.01).
  • Higher age appeared to be the most important factor for withholding treatment since 196 of 286 (68.5%) patients < 70 years, but only 57 of 121 (47.1%) > 70 years underwent adjuvant therapy.
  • 78.4% of patients with UICC IV colorectal cancer (91.8% university hospitals, 76.8% hospital with, 50% without oncological departments, 66.7% rehabilitation clinics, 82.4% private practices) received palliative chemotherapy (first line: 5-FU/FA bolus 57%, 5-FU/FA infusion 20%, 5-FU mono 15%).
  • CONCLUSION: Considering an annual incidence of colorectal cancer in Germany of 52,000 with 30% UICC III, discounting patients > 80 years or ECOG status > 2, and estimating a survival benefit of 10% after adjuvant chemotherapy, approximately 530 lifes are lost annually in Germany due to insufficient treatment of UICC III colorectal cancer based on our survey.
  • In addition, substantial financial demand is generated by the subsequent palliative treatment of potentially curable patients.
  • --In conclusion, survey-based analysis of treatment algorithms can provide valuable insights into clinical practice in oncology and can disclose deficits in patient care as demonstrated here in colorectal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Critical Pathways. Quality Assurance, Health Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Germany. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Palliative Care

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078387.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C: Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology; 2006;70(5):366-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
  • OBJECTIVE: The combined assessment of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) gene expressions in metastatic colorectal cancer has been reported to be able to predict the efficacy of fluoropyrimidine-based chemotherapy.
  • In order to evaluate the prognostic role in the adjuvant setting, we investigated the TS, DPD and TP expression in primary tumors of colorectal cancer patients treated with 5-fluorouracil (5-FU).
  • METHODS: TS, DPD and TP expression levels were determined by immunohistochemistry in paraffin-embedded primary tumor tissues from 62 patients with Dukes' stage B and C colorectal cancers who underwent surgery and received adjuvant systemic chemotherapy with 5-FU.
  • RESULTS: Dukes' stage C cancer and high TS expression were independent markers of poor prognosis for disease-free survival (DFS; p = 0.0009 and p = 0.007, respectively) and overall survival (OS; p = 0.0005 and p = 0.011, respectively).
  • The analysis of Dukes' stage C cancer patients confirmed a significant benefit in terms of DFS and OS (p = 0.001 and p = 0.006, respectively) when all 3 markers had low expression.
  • CONCLUSIONS: This retrospective investigation suggests that the combined assessment of TS and DPD may be useful to evaluate the prognosis of patients with Dukes' B and C colon carcinoma receiving 5-FU adjuvant chemotherapy.
  • The role of TP as a predictor for 5-FU-based therapy needs further investigations.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / enzymology. Dihydrouracil Dehydrogenase (NADP) / metabolism. Fluorouracil / therapeutic use. Thymidine Phosphorylase / metabolism. Thymidylate Synthase / metabolism
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17179731.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Templ E, Mostbeck G, Wagner L, Weissel M: [Spontaneous healing of retroperitonea fibroasis after successful therapy of sigmoid carcinoma]. Acta Med Austriaca; 2000;27(5):168-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneous healing of retroperitonea fibroasis after successful therapy of sigmoid carcinoma].
  • [Transliterated title] Spontanheilung einer Retroperitonealfibrose nach erfolgreicher Therapie eines Sigmakarzinoms.
  • In a 64 year old man sigma cancer was diagnosed unexpectedly during an operation for retroperitoneal fibrosis (histologically benign fibrosis), that had caused unilateral hydronephrosis.
  • In the following hemicolectomy this tumor of the colon turned out to be a medium high grade adenocarcinoma (tumor staging pT2, pN1, DUKES C).
  • Chemotherapy with 450 mg/m2 5-FU once a week and a concomitant therapy with laevamisol was added for 6 months.
  • Computer-tomography revealed a significant reduction of the retroperitoneal masses already before induction of chemotherapy.
  • One year after termination of chemotherapy retroperitoneal fibrosis was no longer detectable.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colectomy. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Remission, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11261269.001).
  • [ISSN] 0303-8173
  • [Journal-full-title] Acta medica Austriaca
  • [ISO-abbreviation] Acta Med. Austriaca
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


27. Sakamoto J, Hamashima H, Suzuki H, Ito K, Mai M, Saji S, Fukushima M, Matsushita Y, Nakazato H: Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial. Oncol Rep; 2003 Sep-Oct;10(5):1081-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial.
  • The expression levels of thymidylate synthase (TS) affect the sensitivity of tumor cells to fluorinated pyrimidine cytotoxic agents and determine the response of patients with colorectal cancer to fluorinated-pyrimidine-based chemotherapy.
  • The correlation between the expression of TS and the prognosis of patients with colorectal cancer was examined in a prospective study.
  • Evaluation of biomarkers including TS expression was performed using tumor specimens from 229 colorectal cancer patients.
  • In a subset analysis of Dukes' stage C patients, the survival and DFS rates were 44.0% and 40.0% in the high TS expression group, and 73.5% and 67.4% in the low TS expression group, respectively.
  • Significantly poorer prognosis of curatively resected colon cancer in patients with high TS expression levels in tumor tissue was confirmed by a double-blind prospective study conducted on samples obtained from patients enrolled in an adjuvant immunochemotherapy randomized clinical trial.
  • [MeSH-major] Colonic Neoplasms / metabolism. Immunotherapy / methods. Thymidylate Synthase / biosynthesis
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / chemistry. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Chemotherapy, Adjuvant. Disease-Free Survival. Double-Blind Method. Epitopes. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Prospective Studies. Pyrimidines / therapeutic use. Random Allocation. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12883662.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Pyrimidines; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


28. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tria Tirona M, Goldberg RM: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol; 2002 Apr 1;20(7):1735-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.
  • PURPOSE: To evaluate the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with Dukes' B2 and C colon carcinoma.
  • METHODS: We conducted a retrospective analysis to evaluate the prognostic value of TS, Ki-67, and p53 in 465 patients with Dukes' B2 (220 patients) or Dukes' C (245 patients) colon carcinoma.
  • Patients represent a nonrandom subset obtained from five randomized phase III trials and were treated with either surgery alone (151 patients) or surgery plus fluorouracil-based chemotherapy (314 patients).
  • Patients whose tumors stained positively for p53 seemed to benefit substantially from the use of adjuvant chemotherapy compared with those who were not treated (P =.05).
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / chemistry. Ki-67 Antigen / analysis. Thymidylate Synthase / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11919229.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA15083; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / CA35101; United States / NCI NIH HHS / CA / CA35103; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA35195; United States / NCI NIH HHS / CA / CA35269; United States / NCI NIH HHS / CA / CA35272; United States / NCI NIH HHS / CA / CA35415; United States / NCI NIH HHS / CA / CA37404; United States / NCI NIH HHS / CA / CA37417; United States / NCI NIH HHS / CA / CA52352; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA63849
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, Sarbia M, Borchard F, Greschniok A, Gruenagel HH, Porschen R, Gregor M: Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis; 2004 Jan;19(1):23-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.
  • BACKGROUND: In the Dukes' B and C stages of colorectal carcinoma there are considerable variations in the observed courses of the disease.
  • Since post-operative chemotherapy in patients with Dukes' C (node-positive) colon carcinoma has been demonstrated to be effective in improving overall-survival, a more exact prognosis assessment gains additional significance and therapeutic relevance.
  • Because of its frequency and the accessibility and recognizability of its developmental stages colorectal carcinoma is among the best investigated of all solid tumors.
  • However, it is to be expected that some of the molecular alterations presently discussed will gain importance before long in the clinical treatment of patients with colorectal carcinoma.
  • [MeSH-major] Carcinoma / genetics. Colorectal Neoplasms / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):298-303 [2438556.001]
  • [Cites] Oncogene. 1996 Aug 15;13(4):787-95 [8761300.001]
  • [Cites] Cancer Lett. 1997 Sep 16;118(1):29-35 [9310257.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):585-90 [7917901.001]
  • [Cites] N Engl J Med. 1994 Jul 28;331(4):213-21 [8015568.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 [11097226.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1855-64 [1532346.001]
  • [Cites] Oncogene. 1996 Jun 20;12(12):2641-9 [8700523.001]
  • [Cites] Eur J Cancer. 2000 May;36(8):1008-15 [10885605.001]
  • [Cites] Br J Cancer. 1997;75(6):903-9 [9062414.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1645-8 [8137274.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):593-9 [10080604.001]
  • [Cites] Eur J Cancer. 1996 May;32A(5):802-6 [9081357.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):988-92 [7862679.001]
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Eur J Cancer. 1998 Mar;34(4):518-21 [9713302.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):544-9 [10749909.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):560-7 [10682666.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):197-201 [10448259.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] J Pathol. 1992 Apr;166(4):329-30 [1517889.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):758-64 [1419618.001]
  • [Cites] Arch Surg. 1993 May;128(5):526-31; discussion 531-2 [8489386.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):549-57 [11330582.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):830-7 [10370622.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):488-92 [10690528.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1842-7 [9667656.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1745-50 [10561211.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Feb;9(2):183-6 [9058631.001]
  • [Cites] Oncology. 1998 May-Jun;55(3):249-57 [9560058.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1515-20 [9673363.001]
  • [Cites] Int J Cancer. 2001 May 20;95(3):162-7 [11307149.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1257-62 [7779721.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1306-10 [7577041.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1405-11 [9815825.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1375-81 [10334521.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1324-31 [7906606.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1318-27 [8413413.001]
  • [Cites] Gut. 1998 May;42(5):669-72 [9659162.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):491-7 [8814697.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):883-90 [10370632.001]
  • [Cites] Gastroenterology. 1993 May;104(5):1535-49 [8482467.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] Biochem Pharmacol. 1995 May 17;49(10):1419-26 [7763285.001]
  • [Cites] J Natl Cancer Inst. 1993 Dec 15;85(24):1978-80 [8246279.001]
  • [Cites] J Pathol. 1996 Dec;180(4):364-70 [9014855.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):255-64 [8625232.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10 ):2371-6 [9796967.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1343-9 [11350904.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1180-7 [9609754.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 30;768:101-10 [8526339.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):325-8 [10037181.001]
  • [Cites] Arch Surg. 1995 Jan;130(1):9-14 [7802584.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):399-402 [8347496.001]
  • [Cites] Dis Colon Rectum. 1994 Jun;37(6):527-34 [8200229.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1760-70 [10561213.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1188-95 [9609755.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):364-72; discussion 372-3 [11289282.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):427-33 [9469325.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):796-804 [9126737.001]
  • [Cites] Semin Oncol. 1999 Dec;26(6):589-605 [10606252.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):216-23 [8688324.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3839-44 [9042267.001]
  • [Cites] Dis Colon Rectum. 1998 Jun;41(6):755-60 [9645744.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1063-72 [10741735.001]
  • [Cites] Cancer. 2000 Nov 15;89(10 ):2025-37 [11066042.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):297-304 [11438476.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Hum Mol Genet. 1996 Sep;5(9):1245-52 [8872463.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1465-9 [9552053.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] J Cell Sci. 1972 Mar;10(2):471-86 [4259666.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):785-90 [9221853.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):358-63 [11289281.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1581-6 [7731713.001]
  • [Cites] J Pathol. 1994 Jan;172(1):5-12 [7931827.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2541-8 [10375100.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1055-60 [7576991.001]
  • [Cites] World J Surg. 1997 Feb;21(2):210-3 [8995081.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2584-8 [3458220.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2203-6 [3829006.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):1996-9 [10473077.001]
  • [Cites] Br J Cancer. 1998;77(3):466-71 [9472645.001]
  • [Cites] Br J Cancer. 1999 Sep;81(2):190-3 [10496341.001]
  • [Cites] Eur J Cancer. 2000 Oct;36(16):2053-60 [11044641.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):1009-22 [7707100.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):310-5 [9221810.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):971-5 [10910245.001]
  • [Cites] Gastroenterology. 1994 Jan;106(1):42-8 [8276207.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):681-7 [8158699.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1149-58 [9515799.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3907-12 [11268475.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1729-35 [8608570.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):260-3 [7678832.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):293-6 [8054278.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1053-6 [7907781.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):727-36 [11241240.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2696-701 [8874329.001]
  • [Cites] Oncogene. 1995 Aug 17;11(4):647-52 [7651727.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):1053-6 [11038045.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1821-6 [10470121.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4797-802 [11156237.001]
  • [Cites] Science. 1993 May 7;260(5109):810-2 [8484120.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1176-81 [7587760.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):233-44 [9010096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):29-35 [9588914.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1364-74 [10334520.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] J Pathol. 1999 May;188(1):14-7 [10398134.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] J Surg Oncol. 1994 Sep;57(1):57-64 [7914949.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1197-202 [10971428.001]
  • [Cites] Br J Cancer. 1997;75(1):87-93 [9000603.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):70-7 [9428481.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2043-50 [7931472.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):42-9 [10618604.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):921-8 [11040179.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):239-44 [11300331.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1243-50 [9607583.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 21;88(16):1110-7 [8757190.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):299-304 [11208819.001]
  • [Cites] Br J Cancer. 1991 Feb;63(2):317-9 [1997114.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1378-84 [10778966.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 1):5405-12 [3931905.001]
  • [Cites] Gut. 1994 Nov;35(11):1627-31 [7828987.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] Gut. 1998 Sep;43(3):383-7 [9863484.001]
  • [Cites] Environ Health Perspect. 1991 Jun;93:125-31 [1685441.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1814-9 [10760757.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):903-8 [10070888.001]
  • [Cites] Cell. 1996 Aug 23;86(4):543-52 [8752209.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):57-64 [8419262.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):635-9 [8631411.001]
  • (PMID = 12827409.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Tumor Suppressor Protein p53; U3P01618RT / Fluorouracil
  • [Number-of-references] 152
  •  go-up   go-down


30. Soran A, Harlak A, Wilson JW, Nesbitt L, Lembersky BC, Wienad HS, O'Connell MJ: Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06. Clin Colorectal Cancer; 2006 Jul;6(2):140-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06.
  • BACKGROUND: Similar epidemiologic characteristics suggest a common etiology for colon cancer (CC) and diverticular disease of the colon (DD).
  • National Surgical Adjuvant Breast and Bowel Project (NASBP) protocol C-06 is a clinical trial comparing oral uracil/tegafur/leucovorin with 5-fluorouracil/leucovorin in patients with resected stage II/III carcinoma of the colon.
  • PATIENTS AND METHODS: The NASBP enrolled 1,608 patients who had undergone potentially curative resection for stage II/III colon cancer from 256 medical sites between February 14, 1997, and March 31, 1999.
  • Colon cancer was located in the rectosigmoid in 46.88% of patients with DD and in 31.92% of patients without DD (P < 0.05).
  • A baseline diagnosis of DD made no significant contribution to DFS or OS without adjustment for confoundin factors (P = 0.2 and P = 0.32, respectively) or adjusted for Dukes classification and age (P = 0.49 and P = 0.68, respectively).
  • There was no negative impact of having DD on DFS and OS in patients treated for stage II/III CC.
  • [MeSH-major] Colonic Neoplasms / complications. Colonic Neoplasms / drug therapy. Diverticulum, Colon / etiology

  • Genetic Alliance. consumer health - Diverticular Disease.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945170.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA-12027; United States / NCI NIH HHS / CA / U10CA-37377; United States / NCI NIH HHS / CA / U10CA-69651; United States / NCI NIH HHS / CA / U10CA-69974
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C, X-ACT Study Group: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol; 2003 Dec;14(12):1735-43
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
  • BACKGROUND: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer.
  • We report here the results of a large phase III trial investigating adjuvant oral capecitabine compared with 5-FU/LV (Mayo Clinic regimen) in Dukes' C colon cancer.
  • PATIENTS AND METHODS: Patients aged 18-75 years with resected Dukes' C colon carcinoma were randomized to receive 24 weeks of treatment with either oral capecitabine 1250 mg/m(2) twice daily, days 1-14 every 21 days (n = 993), or i.v. bolus 5-FU 425 mg/m(2) with i.v. leucovorin 20 mg/m(2) on days 1-5, repeated every 28 days (n = 974).
  • CONCLUSIONS: Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer.
  • Efficacy results are expected to be available in Keywords: Adjuvant treatment, capecitabine, chemotherapy, colorectal cancer

  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14630678.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Brivio F, Fumagalli L, Chiarelli M, Denova M, Bertolini A, Cetta M, Nespoli A: [Immunotherapy in radical surgery of colorectal carcinoma]. Chir Ital; 2007 Sep-Oct;59(5):635-40
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunotherapy in radical surgery of colorectal carcinoma].
  • [Transliterated title] Immuno-modulazione nella chirurgia radicale del carcinoma del colon-retto.
  • Cancer-associated immunodeficiency is seriously worsened by surgical trauma.
  • Growth factors play an important role in oncological practice in treating neutropenia (G-CSF) or associated anaemia during chemotherapy (erythropoietin).
  • The aim of this study was to report on our experience with IL-2 preoperative immunoactivation in colorectal cancer and the long-term outcome of patients treated in comparison with a control group operated on without immunotherapy.
  • In order to obtain activated lymphocytosis at the time of operation administration of IL-2 (6 million I.U. twice daily subcutaneously) for 3 preoperative days is sufficient, starting 4 days before surgery.
  • The inclusion/exclusion criteria were histologically documented colorectal cancer, elective surgery, laparotomic surgery, no second tumour, age 20-80 years, no cardiovascular, hepatic or renal failure.
  • From June 1992 to December 2005, 67 patients were treated (Dukes B/C: 46/21) with IL-2 immunotherapy.
  • The clinical and biological results were compared with those of a control group of 173 patients (Dukes B/C 114/59) operated on in the same period and recruited with the same criteria.
  • Dukes stage-C patients in both groups underwent adjuvant chemotherapy plus radiotherapy for rectal cancer.
  • Data were statistically analysed using Fisher's exact test, Student's T-test and analysis of variance, as appropriate.
  • Important results were obtained in Dukes-B patients: progression rate 7/46 (15%) vs 37/114 (32,4%) in controls (p = 0.03).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / immunology. Colorectal Neoplasms / surgery. Digestive System Surgical Procedures / adverse effects. Immunologic Deficiency Syndromes / drug therapy. Immunotherapy / methods. Interleukin-2 / therapeutic use. Neoadjuvant Therapy / methods
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Neoplasm, Residual / immunology. Neoplasm, Residual / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019635.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


33. Lin JT, Wang WS, Yen CC, Liu JH, Yang MH, Chao TC, Chen PM, Chiou TJ: Outcome of colorectal carcinoma in patients under 40 years of age. J Gastroenterol Hepatol; 2005 Jun;20(6):900-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of colorectal carcinoma in patients under 40 years of age.
  • AIMS: Colorectal carcinoma in patients under 40 years of age usually has a poor prognosis.
  • Controversies still exist regarding the features and the prognosis of colorectal cancer in young patients.
  • METHODS: The records of 45 patients with histologically confirmed colorectal carcinoma treated between 1992 and 2002 at the Division of Oncology at Taipei Veterans General Hospital were reviewed.
  • The relevance of sex, duration of symptoms, tumor site, histological type, lymph node involvement, Karnofsky performance status (KPS), carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) levels at the diagnosis and tumor stage to overall survival (OS) were determined by univariate analysis, and their independent significance were tested by multivariate analysis.
  • RESULTS: Most patients presented with an advanced tumor stage (24% Dukes' C and 66% Dukes' D).
  • Colon carcinoma constituted 76% of the colorectal tumors.
  • Two patients were found to have colon carcinoma during pregnancy.
  • The 5-year survival rate in patients with Stage B, C, and D were 25, 16 and 0%, respectively.
  • With aggressive treatment, patients with early stage carcinoma achieved longer survival.
  • Eleven patients received resection of metastatic carcinoma of the liver, lung and ovary.
  • Adjuvant chemotherapy with irinotecan/5-fluorouracil-based chemotherapy seemed to improve the OS in such patients, though the OS was still poorer than in patients with early stage tumors.
  • In univariate analysis, KPS (P = 0.0001), lymph node involvement (P = 0.0024), CEA (P = 0.0423) and LDH levels (P = 0.0126) at the diagnosis and tumor stage (P = 0.0122) proved to be significant predictors of overall survival.
  • CONCLUSIONS: The present study shows that performance status and preoperative LDH levels were the major determinants for survival in patients with colorectal carcinoma under 40 years of age and the present series also suggests that surgical resection of metastatic colorectal carcinoma followed by adjuvant chemotherapy might be beneficial in certain patients.
  • The data also suggests that current treatment modalities for young patients with advanced colorectal cancer might not be effective and more effective therapeutic regimens might be needed.
  • Thus, it is important for surgeons to recognize the potential for colorectal cancer in young patients and to take an aggressive approach to the diagnosis and early treatment of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 15946138.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


34. Vastyan AM, Walker J, Pintér AB, Gerrard M, Kajtar P: Colorectal carcinoma in children and adolescents--a report of seven cases. Eur J Pediatr Surg; 2001 Oct;11(5):338-41
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma in children and adolescents--a report of seven cases.
  • Carcinoma of the colon and rectum is uncommon in this age group and has a poor prognosis.
  • Five patients had Dukes' stage C and two had Dukes' stage D tumour.
  • Post-operative chemotherapy was given to six patients and two had post-operative radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Pediatr Surg. 2003 Aug;13(4):287 [13680503.001]
  • (PMID = 11719875.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Ishida H, Tatsuta M, Furukawa H, Ohta H, Hashimoto K, Hayashi N, Morimoto O, Ikeda M, Miya A, Masutani S, Kawasaki T, Satomi T, Yoshioka H, Hanai J: Multiple inflammatory pseudotumors mimicking liver metastasis from colon cancer: report of a case. Surg Today; 2000;30(6):530-3
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple inflammatory pseudotumors mimicking liver metastasis from colon cancer: report of a case.
  • A 54-year-old man underwent an operation for colon cancer histologically diagnosed as moderately differentiated adenocarcinoma with clinical staging of Dukes C.
  • He was prescribed carmofur for adjuvant chemotherapy.
  • A follow-up computed tomography scan done 6 months later revealed two new low-density areas in the liver.
  • A diagnosis of metastatic adenocarcinoma from the previous colon cancer was presumed, based on the patient's history and radiological findings, and resection of the affected area of liver was performed.
  • IPT of the liver is a rare disease, for which no methods of diagnosis and treatment have been established, since it is difficult to distinguish IPT from hepatocellular carcinoma or metastatic carcinoma.
  • We describe this case with a review of the 101 cases of IPT documented in the Japanese literature, in the hope that it will contribute to the diagnosis and treatment of this unusual disease entity.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Granuloma, Plasma Cell / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1989 Mar-Apr;33(2):259-62 [2929226.001]
  • [Cites] Am J Clin Pathol. 1978 Feb;69(2):176-81 [629225.001]
  • [Cites] J Surg Oncol. 1989 Apr;40(4):283-7 [2927142.001]
  • [Cites] J Clin Pathol. 1997 Apr;50(4):352-3 [9215157.001]
  • [Cites] Am J Gastroenterol. 1998 Sep;93(9):1538-40 [9732940.001]
  • [Cites] Ann Surg. 1953 Aug;138(2):253-8 [13066016.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1583-90 [2155699.001]
  • (PMID = 10883465.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


36. Gennatas C, Mouratidou D, Androulakis G, Georgoulias V, Tsavaris N, Philippakis M, Michailakis E, Kalofonos C, Mpesmpeas S, Katsos J, Tsitoura M, Retalis G, Mallas E, Voros D, Andreadis C, Hatzistylianos G, Pisiotis C, Kamilarios D, Kakoliris S, Komporozos V, Kannas D, Legakis N, Mpatakis T, Ntamtsios J, Papaevangelou E, Peros G, Photopoulos A, Pouli A, Prigouris S, Samanidis L, Sakellariou V, Smyrniotis V, Polymeneas G, Vasiliou J, Athanasiou A, Papadimitriou J: Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma. Tumori; 2002 Jan-Feb;88(1):32-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma.
  • AIMS AND BACKGROUND: Trials of adjuvant systemic therapy in high risk patients with Dukes' B2 and C colon cancer utilizing 5-fluorouracil-based regimens have been ongoing since the 1960s.
  • STUDY DESIGN: A total of 322 patients with histologically proven adenocarcinoma of the colon, Dukes' stage B2 and C, were entered in the study.
  • They were randomized to A) leucovorin 20 mg/m2 rapid intravenous injection and 5-FU 425 mg/m2 IV days 1-5 every 28 days for six cycles or B) 5-FU 600 mg/m2 24-hour infusion for five days, then 600 mg/m2 IV once a week and IFN 5 MU subcutaneously three times a week for six months.
  • These data do not support the use of IFN in combination with 5-FU as systemic adjuvant therapy for patients with locally advanced colon carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Interferon-alpha / administration & dosage. Leucovorin / administration & dosage. Male. Neoplasm Staging. Recombinant Proteins. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004847.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Salas-Valverde S, Lizano A, Gamboa Y, Vega S, Barrantes M, Santamaría S, Zamora JB: Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases. Pediatr Surg Int; 2009 Dec;25(12):1073-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases.
  • BACKGROUND: Carcinoma of the colon and rectum is rare in the pediatric age group, and usually presents with an advanced stage disease bearing a poor prognosis.
  • Colorectal carcinoma should be considered in children with signs of intestinal obstruction, alteration in bowel habits, gastrointestinal bleeding and chronic abdominal pain.
  • METHODS: Between 1974 and 2007, 11 patients were identified and treated for colorectal carcinoma at the Oncology Unit.
  • The medical records were studied to analyze the age, sex, clinical presentation, diagnostic procedures, extent of disease (Dukes staging), treatment, histological types, and outcome.
  • Predisposing diseases and syndromes were encountered in three children, (1 with Turner's syndrome and two with adenomatous familial polyposis).
  • Surgical procedures were done in 11 patients (incomplete resection with segmental resection in 4 patients, complete resection in the other 4, and biopsy alone in 3 patients).The predominant histological type was mucinous carcinoma.
  • Seven patients received adjuvant chemotherapy, all of whom did not survive.
  • CONCLUSIONS: Colorectal carcinoma in children is very uncommon and could be easily misdiagnosed, resulting in advanced stage disease at diagnosis.
  • Because radical surgery which is the mainstay of treatment is possible only in patients with early stage disease, a high level of awareness and early diagnosis are critical.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Antineoplastic Agents / therapeutic use. Colectomy / methods. Colonic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Biopsy. Chemotherapy, Adjuvant. Child. Colonoscopy. Costa Rica / epidemiology. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Prognosis. Retrospective Studies. Survival Rate / trends

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):39-41 [15654277.001]
  • [Cites] Cancer. 1958 Jul-Aug;11(4):855-7 [13561255.001]
  • [Cites] Surg Gynecol Obstet. 1962 Apr;114:438-42 [13898554.001]
  • [Cites] J Pediatr Surg. 1976 Dec;11(6):967-71 [1003308.001]
  • [Cites] Clin Genet. 1987 Jan;31(1):35-44 [3568432.001]
  • [Cites] Am Surg. 1998 Sep;64(9):849-53 [9731812.001]
  • [Cites] Pediatrics. 1963 Oct;32:558-71 [14069097.001]
  • [Cites] J Chemother. 2002 Jun;14(3):301-8 [12120887.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1085-9; discussion 1089-90 [1403541.001]
  • [Cites] Eur J Pediatr Surg. 2003 Feb;13(1):66-8 [12664421.001]
  • [Cites] Dis Colon Rectum. 1976 Sep;19(6):529-34 [183939.001]
  • [Cites] Eur J Pediatr Surg. 2001 Oct;11(5):338-41 [11719875.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):952-5 [4016687.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1322-6 [3971300.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):919-21 [1640344.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1188-93 [8308690.001]
  • [Cites] Arch Surg. 1970 Apr;100(4):527-31 [4190476.001]
  • [Cites] Dis Colon Rectum. 1981 Jan-Feb;24(1):25-8 [7472098.001]
  • [Cites] Surgery. 1983 Mar;93(3):409-14 [6600855.001]
  • [Cites] Am J Surg. 1958 Jul;96(1):47-53 [13545485.001]
  • [Cites] Surg Gynecol Obstet. 1974 Feb;138(2):169-70 [4810853.001]
  • [Cites] Br J Surg. 1984 Apr;71(4):272-7 [6704677.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1560-2 [14605580.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2464-72 [200342.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):209-11 [17255833.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Pediatr Surg. 1989 Nov;24(11):1189-91 [2553912.001]
  • [Cites] South Med J. 1976 Jan;69(1):24-7 [1246645.001]
  • (PMID = 19816697.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


38. Tokatli F, Koçak Z, Ozyilmaz F, Uygun K, Caloglu M, Uzal C: Small cell carcinoma of the rectum; report of a case. J BUON; 2002 Jan-Mar;7(1):75-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the rectum; report of a case.
  • Primary small cell undifferentiated carcinoma of the colon and rectum is a relatively rare tumour with an overall incidence of less than 1% among all colorectal cancers.
  • Despite the mean survival being around 6 months, long-term survival may be achieved in patients with localized disease treated with curative resection and adjuvant therapy.
  • We report on a patient with Dukes' C small cell carcinoma (SCC) of the rectum who underwent surgery followed by pelvic irradiation and chemotherapy and achieved long-term survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577266.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


39. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst; 2004 Aug 4;96(15):1128-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
  • BACKGROUND: The National Surgical Adjuvant Breast and Bowel Project C-01 trial reported in 1988 that, for patients with adenocarcinoma of the colon, compared with surgery alone, 1) postoperative chemotherapy with 1-(2-chloroethyl)-3-(4-trans-methylcyclohexyl)-1-nitrosourea (i.e., MeCCNU or semustine), vincristine, and 5-fluorouracil was associated with better 5-year disease-free and overall survival and 2) postoperative immunotherapy with bacillus Calmette-Guérin was associated with better 5-year overall, but not disease-free, survival.
  • METHODS: Between November 11, 1977, and February 28, 1983, 1166 patients with resected Dukes' stage B and C adenocarcinoma of the colon were stratified by Dukes' stage, sex, and age (<65 years or > or =65 years) and then randomly assigned to receive no further treatment (surgery alone; 394 patients), adjuvant chemotherapy (379 patients), or adjuvant immunotherapy (393 patients).
  • Those eligible for follow-up included 375 (95.2%) patients in the surgery-alone group, 349 (92.1%) patients in the adjuvant-chemotherapy group, and 372 (94.7%) patients in the adjuvant-immunotherapy group.
  • RESULTS: No difference was observed between patients in the chemotherapy group and those in the surgery-alone group in 10-year disease-free survival (hazard ratio [HR] = 1.14, 95% confidence interval [CI] = 0.94 to 1.39;P =.17) or overall survival (HR = 1.12, 95% CI = 0.91 to 1.38; P=.27).
  • CONCLUSION: The disease-free and overall survival benefit associated with chemotherapy in this patient population is of limited duration, disappearing after 10 years.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / surgery. Immunotherapy / methods. Mycobacterium bovis / immunology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Likelihood Functions. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Proportional Hazards Models. Randomized Controlled Trials as Topic. Semustine / administration & dosage. Survival Analysis. Treatment Outcome. United States. Vincristine / administration & dosage

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Semustine .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2004 Dec 1;96(23):1794; author reply 1794 [15572762.001]
  • [CommentIn] J Natl Cancer Inst. 2004 Aug 4;96(15):1116-7 [15292377.001]
  • (PMID = 15292384.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 13909-09-6 / Semustine; 5J49Q6B70F / Vincristine; U3P01618RT / Fluorouracil; MOF protocol
  •  go-up   go-down


40. Van Laethem JL: Adjuvant treatment for colorectal cancer. Acta Gastroenterol Belg; 2001 Jul-Sep;64(3):263-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment for colorectal cancer.
  • Colorectal cancer is a leading cause of cancer in Western countries.
  • Recent trials led to the general acceptance of adjuvant chemotherapy in Dukes C cancer by identifying bolus 5FU and leucovin during 6 months (5 days monthly) as the current standard.
  • The role of adjuvant chemotherapy remains questionable in Dukes B2 (stage II) colon cancer, in rectal cancer and after curative resection of liver metastases.
  • The development of total mesorectum excision (TME) technique has dramatically resulted in improving local recurrence control and will be the standard in rectal cancer surgery; preoperative irradiation is widely used in Europe for stage II and III rectal cancer but its definite place and its optimal regimen await further assessment as well as the role of adjuvant chemotherapy in rectal cancer.
  • New chemotherapeutic combinations based on new effective agents in colorectal cancer such as CPT-11 and oxaliplatine have been currently used for downstaging liver metastases initially unresectable.
  • This new approach, combined with the development of local ablative therapies such as cryotherapy and radiofrequency allows curative strategies in a significant number of patients primarily unfit for surgical resection of liver mets.
  • The present paper aims to review the different aspect of (neo)adjuvant therapies in the multimodal curative management of colorectal cancers.
  • [MeSH-major] Carcinoma / drug therapy. Chemotherapy, Adjuvant. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Neoplasm Staging. Survival Rate. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11680045.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 45
  •  go-up   go-down


41. Osuagwu CC, Okafor OC, Ezeome ER, Uche CE, Ememonu C, Kesieme E: Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male. Rare Tumors; 2010;2(4):e66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male.
  • An intriguing feature of this case is an ulcerated jejunal carcinoma which was metastatic rather than synchronous carcinoma.
  • This patient presented with partial large bowel obstruction and the pathological analysis revealed 4 invasive adenocarcinomas, 3 in the colon and 1 in the jejunum (Dukes stage D).
  • Palliative pancolectomy and jejunal tumour resection with chemotherapy was offered to him.
  • The challenges of managing a hereditary cancer syndrome in a resource poor country are highlighted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Nov 14;14(42):6531-5 [19030207.001]
  • [Cites] East Afr Med J. 1995 Apr;72(4):267-8 [7621765.001]
  • [Cites] West Afr J Med. 2001 Oct-Dec;20(4):251-5 [11885882.001]
  • [Cites] Cent Afr J Med. 1992 Jan;38(1):44-8 [1321689.001]
  • [Cites] Niger J Med. 2005 Apr-Jun;14(2):161-6 [16083239.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cent Afr J Med. 1994 Jan;40(1):8-13 [8082150.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] JOP. 2008;9(1):9-18 [18182737.001]
  • [Cites] Neth J Med. 1989 Jun;34(5-6):317-21 [2549435.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1982-7 [8247073.001]
  • [Cites] Dis Colon Rectum. 1996 May;39(5):536-40 [8620804.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • (PMID = 21234258.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019601
  • [Keywords] NOTNLM ; adenocarcinoma. / colon / familial adenomatous polyposis / jejunum
  •  go-up   go-down






Advertisement